Clinicopathological features and prognosis of intestinal hepatoid adenocarcinoma: evaluation of a pooled case series

Xiangyu Zeng; Peng Zhang; Hua Xiao; Xiuli Wu; Weizhen Liu; Jun He; Jinbo Gao; Guobin Wang; Xiaoming Shuai; Kaixiong Tao

doi:10.18632/oncotarget.23595

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Clinicopathological features and prognosis of intestinal hepatoid adenocarcinoma: evaluation of a pooled case series

Xiangyu Zeng, Peng Zhang, Hua Xiao, Xiuli Wu, Weizhen Liu, Jun He, Jinbo Gao, Guobin Wang, Xiaoming Shuai and Kaixiong Tao _

PDF | HTML | How to cite

Oncotarget. 2018; 9:2715-2725. https://doi.org/10.18632/oncotarget.23595

Metrics: PDF 2172 views | HTML 2204 views | ?

Abstract

Xiangyu Zeng1, Peng Zhang1, Hua Xiao2, Xiuli Wu3, Weizhen Liu1, Jun He3, Jinbo Gao1, Guobin Wang1, Xiaoming Shuai1 and Kaixiong Tao1

1Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China

3Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Correspondence to:

Kaixiong Tao, email: [email protected]

Xiaoming Shuai, email: [email protected]

Keywords: hepatoid adenocarcinoma; intestines; stomach; feature; prognosis

Received: May 10, 2017 Accepted: December 15, 2017 Published: December 21, 2017

ABSTRACT

Backgroud: Intestinal hepatoid adenocarcinoma (IHA) is a very rare and unique intestinal malignancy. Due to the lack of case series specifically pertaining to IHA, the clinicopathological features and prognosis of it remain unclear.

Results: Of the 42 patients enrolled in this study, 30 (71.4%) were male. Twenty-one cases (50.0%) were located in the colon. Eight cases (19.0%) had accompanying inflammatory bowel disease (IBD). Elevated serum alpha-fetoprotein (AFP) was detected for most patients (25/33, 84.8%). Twenty-five (59.5%) patients received complete resections. Vascular invasion (22/36, 61.1%), lymph node metastasis (28/36, 77.8%) and distant metastasis (21/42, 50.0%) were common. The 1-year progression-free survival (PFS) and disease-specific survival (DSS) of IHA were 26.9% and 30.6%, respectively. Multivariate analysis showed that only pTNM stage was an independent risk factor for PFS and DSS. PFS and DSS in patients with IHA were significantly lower than those with colorectal adenocarcinoma (CA) and hepatoid adenocarcinoma of the stomach (HAS).

Conclusions: IHA most commonly occurred in the colon and accompanied by IBD in several cases. pTNM stage was an independent factor for prognosis. The prognosis of IHA was significantly worse than that of CA and HAS.

Patients and Methods: Clinical data of IHA from four patients managed at our institution between January 2010 and December 2016, and 38 cases from research databases prior to 2017 were retrospectively studied.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23595

Publication Alerts

Research Papers:

Clinicopathological features and prognosis of intestinal hepatoid adenocarcinoma: evaluation of a pooled case series

Abstract